ライフサイエンスコーパス: pmol

1 ntricle (RV) (31.1 pmol/l [IQR: 21.8 to 56.0 pmol/l]), and the lowest values were seen in patients wi

2 Lu-DOTATATE, injection of 10, 200, and 2,000 pmol of (177)Lu-OPS201 did not cause any relevant tumor

3 p = 1.00; n = 46,186); fasting insulin (0.01 pmol/l [95% CI -0.00, 0.01,]; p = 0.22; n = 46,186); BMI

4 profound antinociception (i.t. ED50 = 0.0146 pmol/mouse) that was 2000x greater than morphine.

5 detection to 1.13 pmol g(-1) h(-1) and 0.02 pmol g(-1) h(-1), respectively, suggesting that sediment

6 N2 fixation rates were up to 3.02 pmol N copepod(-1) day(-1).

7 ately 9.5 muM and Vmax of approximately 0.04 pmol/min per ng of protein.

8 e the minor T-allele associated with a 0.057 pmol/L higher pro-ENK level per allele (P=4.67x10(-21)).

9 metabolite (TX-M; 1.4 +/- 0.3 vs 0.9 +/- 0.1 pmol/mg Cr, P < .01) levels were higher in group II than

10 unchanged, whereas TX-M levels (0.7 +/- 0.1 pmol/mg Cr, P = .07) tended to decrease in group I.

11 oduction at the dose of 2.6 mumol/min by 1.1 pmol.min(-1).100 mL(-1) tissue (95% confidence interval,

12 als = 99), but lowered fasting insulin (-1.1 pmol/L; -1.7, -0.5; n = 90).

13 imal transport rates (Vmax) of 25.9 and 10.1 pmol/min/oocyte, respectively.

14 The median NT-proBNP level was 15.1 pmol/l (interquartile range [IQR]: 7.1 to 31.3 pmol/l),

15 A mean FAD synthesis rate of 18.1 pmol.min(-1).mg(-1) protein was estimated by both HPLC a

16 gon-like polypeptide 1 (mean difference, 2.1 pmol/L [95% CI, 0.9-3.2]; P = .01).

17 ]) and a systemic right ventricle (RV) (31.1 pmol/l [IQR: 21.8 to 56.0 pmol/l]), and the lowest value

18 levosimendan treatment (from 252.1 +/- 31.1 pmol/l at baseline to 215.02 +/- 27.96 pmol/l at 6 h, p

19 ed in patients with Fontan circulation (36.1 pmol/l [IQR: 14.4 to 103.8 pmol/l]) and a systemic right

20 ients and controls were 45.8 pmol/l and 45.1 pmol/l, respectively (p = 0.86).

21 ranged from below the detection limit of <1 pmol L(-1) to 5 pmol L(-1), with average concentrations

22 A8, and 1A10 were below detection limits (<1 pmol/mg protein) in human liver microsome (HLMs).

23 nts on the level of sub-10 ng or picomole (1 pmol).

24 the minimum detectable concentration was ~1 pmol in contrast to ~5 nmol in the colorimetric assay.

25 6 vs. 0.7 +/- 0.6 x 10(-4) dL kg(-1) min(-1) pmol/L(-)(1) at w0 vs. w6-HFD [P < 0.05], respectively;

26 mals (1.8 +/- 0.3 x 10(-4) dL kg(-1) min(-1) pmol/L(-1) at HFD + RDN [P < 0.001] vs. w6-HFD, [P not s

27 3 vs. 0.5 +/- 0.3 x 10(-4) dL kg(-1) min(-1) pmol/L(-1) at w0 vs. w6-HFD [P < 0.001], respectively).

28 d Kd were 1.15 +/- 0.12 nM and 3.03 +/- 0.10 pmol/mg, respectively, in HEK293-hP2X7R membranes.

29 lasma aldosterone (149 +/- 18 vs. 109 +/- 10 pmol/L, P = 0.003), and urinary protein excretion (61 [3

30 essin type 1a receptor agonist FE 202158 (10 pmol.kg(-1).min(-1)), or vehicle (0.9% NaCl) (n = 6 each

31 ebroventricular injection of LMW AbetaOs (10 pmol) induced rapid and persistent cognitive impairment

32 d, memory deficit induced by HMW AbetaOs (10 pmol) was found to be reversible.

33 res of isolated FFAs to values in the low 10 pmol range.

34 0 pmol) versus high ( approximately 1 MBq/10 pmol) peptide amount of (177)Lu-NeoBOMB1, after which bi

35 pancreas (200 pmol, 570 vs. 265 mGy/MBq; 10 pmol, 435 vs. 1393 mGy/MBq).

36 c-SARNC bolus (185 kBq [5 muCi], 100 muL, 10 pmol of peptide +/- 40 nmol of Tyr(4)-BBN: in vivo GRPR

37 4, 74, or 370 kBq, respectively, 100 muL, 10 pmol total peptide +/- 40 nmol Tyr(4)-BBN: for in vivo G

38 as 15.6 h (13.4-17.7) for (177)Lu-OPS201 (10 pmol) and 6.4 h (5.4-7.3) for (177)Lu-DOTATATE, resultin

39 terone and -4% (95% CI, -0.5% to -7%) per 10 pmol/L decrease in free testosterone.

40 nearly with thrombin concentrations up to 10 pmol L(-)(1), the detection limit being 1x10(-)(1)(3) mo

41 s strongly increased in the liver (from 100 pmol/g to 500 pmol/g) independent of adrenals.

42 beled biomolecules (typically 50 pmol to 100 pmol) is quite challenging and often limits the possible

43 al keratinocytes, with triiodothyronine (100 pmol/L) or thyroxine (100 nmol/L).

44 c Gd concentrations in SFB, from 8.27 to 112 pmol kg(-1) over the past two decades, and reach the nor

45 per ocean, a Pb concentration maxima (64-113 pmol kg(-1)) extended throughout the entire North Pacifi

46 pectively) and fructose (Vmax of 406 and 116 pmol/min/oocyte for GLUT2 and GLUT8, respectively).

47 for melatonin synthesis were 500 muM and 12 pmol/min.mg protein, respectively.

48 tion rate of 0.48 +/- 0.09 and 0.79 +/- 0.12 pmols/day for syn- and anti-DP, respectively.

49 with serum vitamin B-12 concentrations <120 pmol/L at screening.

50 The first group (SB-12 <126 pmol/L) was small and had the highest MMA concentration

51 re low, ranging from below detection to 1.13 pmol g(-1) h(-1) and 0.02 pmol g(-1) h(-1), respectively

52 yer corresponded to a surface coverage of 13 pmol cm(-2).

53 he lower limit of detection was 1 mug/L (130 pmol/L).

54 n B-12 group (mean +/- SD change: 81 +/- 135 pmol/L for vitamin B-12 and 26 +/- 34 pmol/L for holotra

55 T in vitro (CTB: 96 +/- 16 vs SCT: 46 +/- 14 pmol O2 x min(-1) x 100 ng DNA(-1), p < 0.001) and (CTB:

56 cTnI at 0 h were detected with copeptin >14 pmol/l in 10 (53%) of 19 patients.

57 cTnI alone were picked up with copeptin >14 pmol/l in 23 (72%) of 32 patients.

58 1.3 pmol/l), and the NT-proBNP level was >14 pmol/l in 53% of patients.

59 ange: 7.0 to 19.8 pmol/l]) was elevated (>14 pmol/l) in 38% of patients.

60 Elevated NT-proBNP (>14 pmol/L), elevated high-sensitive troponin-T (>14 ng/L),

61 was to demonstrate that copeptin levels <14 pmol/L allow ruling out acute myocardial infarction (AMI

62 g N-nitrosamines ranged between 0.07 muM (14 pmol injected) and 0.13 muM (26 pmol injected).

63 plasma total vitamin B-12 concentration <148 pmol/L (deficient) or 148-220 pmol/L (marginal) increase

64 y and birth weight, but B12 deficiency (<148 pmol/L) was associated with a higher risk of low birth w

65 croglia antagonists (50 nl) (PACAP(6-38), 15 pmol; minocycline 10 mg/ml) microinjected bilaterally in

66 (<1 min) and moderate sample consumption (15 pmol DNA) suggest potential for research and clinical ap

67 ow the limit of detection (350 fmol/g) to 15 pmol/g wet brain.

68 high concentrations in all dust (median 154 pmol/g) and food samples (median 0.7 pmol/g lw) but was

69 usion of sub-pathological dose of Abeta (160 pmol Abeta1-42/day i.c.v) for 14 days.

70 6- to 12-hour time point; 95% CI, -32 to 160 pmol/L).

71 2.5 x 10(-35)) and serum insulin (beta = 165 pmol l(-1), P = 1.5 x 10(-20)) 2 hours after an oral glu

72 ficient in producing the AM at a rate of 167 pmoles AM/min/mg HLM.

73 ectrometry quantification showed that 32-169 pmol/mg protein of 3-deoxythreosone-derived hydroimidazo

74 the placebo group (-27 +/- 64 and -5 +/- 17 pmol/L, respectively) after adjustment for baseline conc

75 e placebo group (0.06 [0.16] vs -0.04 [0.17] pmol/L) (P = .04).

76 concentrations were 210 pmol/L (61) and 172 pmol/L (49), respectively.

77 (3.47-13.9 nmol/L, or free testosterone <173 pmol/L) were randomly assigned (1:1), via computer-gener

78 ict hospital mortality was approximately 175 pmol/L, and higher levels were associated with mortality

79 ulated C-peptide: transported 788 (114-1764) pmol/L (n = 9); locally isolated 407 (126-830) pmol/L (n

80 SEM; incremental AUCinsulin 11,000 +/- 1800 pmol/L .min compared with 18,700 +/- 3100 pmol/L .min, P

81 s with a serum vitamin B-12 deficiency (<185 pmol/L) had higher risk of incident early and late AMD [

82 210-1880), 290 (140-690), and 440 (160-1940) pmol/L at 2 wk, 4 mo, and 9 mo, respectively; the respec

83 in C-peptide area under the curve of -0.195 pmol/mL (95% CI -0.292 to -0.098) and those in the place

84 - SD) [2.4 +/- 0.2 compared with 1.3 +/- 0.2 pmol 7-amido-4-methylcoumarin (AMC) . mug protein(-)(1)

85 (threshold limit 0.10 x 10(-3) U, i.e., 0.2 pmol), and C1Inh function was quantified in the sample,

86 eosone-derived hydroimidazolone and 1.1-11.2 pmol/mg protein of 3-deoxythreosone-derived hydroimidazo

87 n of the substrate occurred at a rate of 2.2 pmol min(-1) mg(-1) and was also effectively inhibited b

88 ated dephosphorylation of the substrate (2.2 pmol min(-1) mg(-1)) that was blocked by pretreatment of

89 oxic at doses ranging from 32 fmol/kg to 3.2 pmol/kg.

90 after 90 min compared with placebo (mean 3.2 pmol/L [SD 0.86] vs 2.1 [0.65], p=0.004), increased insu

91 en had median copeptin levels of 3.0 and 5.2 pmol/L, respectively (P<0.001).

92 l/kg/min; n = 8) and insulin-327 (Pe327; 7.2 pmol/kg/min; n = 5) was infused peripherally.

93 nstrated sensitivity down to approximately 2 pmol of S(14)NO groups and approximately 5 pmol of S(15)

94 ion from approximately 10 to approximately 2 pmol/mL and from approximately 40 to approximately 10 mu

95 ingle cells, occurred at rates of at least 2 pmol min(-1) mg(-1).

96 s was found to be identical and was 10 nM (2 pmol), similar to analogous QD-FRET using labeled oligon

97 nternal consistency of the suite within +/-2 pmol/mol.

98 in spiked human serum was 4 ng mL(-1) (10(2) pmol L(-1)), a value within the range of clinically rele

99 n 5% relative standard deviation (RSD) at 20 pmol for non-species-specific ID LC-ICPMS and 500 pmol f

100 doses (specific activities) of less than 20 pmol (>1,000 MBq/nmol) and 1 nmol (20 MBq/nmol) per mous

101 When less than 20 pmol was applied, high uptake of (68)Ga-aquibeprin in th

102 The reduction was similar for 10 and 200 pmol, whereas lysine performed better than succinylated

103 In HeLa cells, at 200 pmol ASO (with PA:LFN-GAL4), 5.4 +/- 2.0% Synt5 expressi

104 -NeoBOMB1 or a low ( approximately 1 MBq/200 pmol) versus high ( approximately 1 MBq/10 pmol) peptide

105 d dose to the tumor versus the pancreas (200 pmol, 570 vs. 265 mGy/MBq; 10 pmol, 435 vs. 1393 mGy/MBq

106 eptide mass of (177)Lu-OPS201 from 10 to 200 pmol drastically decreased the effective dose from 0.090

107 Using 200 pmol ASOs, Nucleofection(R) reduced Synt5 expression to

108 y) Synt5 expression after treatment with 200 pmol of ASO and demonstrated versatility.

109 ations of at least 27 +/- 6 mM or 104 +/- 21 pmol m(-3).

110 (serum vitamin B-12 concentrations: 107-210 pmol/L) in the absence of anemia and received 1 mg cryst

111 vitamin B-12 concentrations >/=107 and <210 pmol/L without anemia, n = 201).

112 nd free testosterone concentrations were 210 pmol/L (61) and 172 pmol/L (49), respectively.

113 rate (mean +/- SEM, 107 +/- 8 vs. 235 +/- 22 pmol/min/30,000 cells; P < 0.001), produced more superox

114 luble activities of 151 +/- 20 and 36 +/- 22 pmol/min/mug, respectively.

115 entration <148 pmol/L (deficient) or 148-220 pmol/L (marginal) increased with pregnancy and pregnancy

116 TGN concentrations of >220 pmol/8 x 10(8) RBCs are associated with remission.

117 An avTGN concentration of >220 pmol/8 x 10(8) RBCs best predicted remission, with an od

118 lasma total vitamin B-12 concentration (>220 pmol/L).

119 stosterone concentrations increased from 222 pmol/L (62) to 364 pmol/L (222).

120 hange in C-peptide area under curve was -229 pmol/L (95% CI -316 to -142) for the treatment group and

121 had lower NT-proANP levels (1427 versus 2291 pmol/L; P<0.001) and higher diastolic blood pressures (7

122 ation of vitamin B-12 (641 compared with 231 pmol/L), a 331% increase in serum holotranscobalamin (24

123 ive: 613(300-1090); DSA positive 106(34-235) pmol/L [p = 0.004]).

124 he placebo group had a mean change of -0.239 pmol/mL (-0.361 to -0.118) in the placebo group (p=0.591

125 vel (0.86 to 1.90 ng per deciliter [11 to 24 pmol per liter]), and for hypothyroxinemia, defined as a

126 Single topical administration of 25 pmol of 12 increased tear volume in wild-type mice with

127 r thousand for OSCs at a concentration of 25 pmol or 1.4 ppm, and better than 0.5 per thousand for co

128 Injection of approximately 250 pmol (68)Ga-NeoBOMB1 resulted in a tumor and pancreas up

129 njected with either approximately 13 MBq/250 pmol (68)Ga-NeoBOMB1 or a low ( approximately 1 MBq/200

130 ation on S6K (RPS6KB1) with an EC(50) of 250 pmol/L with approximately 800-fold selectivity for cellu

131 ridinoline cross-link concentration of >2500 pmols g(-1) dry mass.

132 16 to -142) for the treatment group and -253 pmol/L (-383 to -123) for the placebo group; this differ

133 (minimum-maximum) insulin concentration (254 pmol/L [88-797 pmol/L]), and median C-peptide concentrat

134 0.07 muM (14 pmol injected) and 0.13 muM (26 pmol injected).

135 -dietary oil [3293 +/- 404 and 1674 +/- 270 (pmol/L) x 120 min; P = 0.002].

136 The limits of detection range from 7 to 278 pmol.

137 The highest SB-12 group (SB-12 >287 pmol/L; n = 8569, 67.6%) likely had adequate vitamin B-1

138 mmol/L (SD 0.66), mean fasting insulin 71.29 pmol/L (47.72), and mean HOMA2-IR 1.35 (0.91).

139 115% (5.3 +/- 0.4 compared with 2.5 +/- 0.3 pmol AMC . mug protein(-)(1) . min(-)(1); P < 0.001) gre

140 ratively lower concentrations (17 versus 0.3 pmol/mg of protein), and 3-Cl-Tyr could not be detected.

141 when added to clinical scores; levels <133.3 pmol/l and >211.3 pmol/l detected low-risk and high-risk

142 f E2 for all male subjects was 50.1 +/- 16.3 pmol/L, significantly higher compared to 13.8 +/- 11.8 p

143 ; n = 23), 2 h post-challenge insulin (-20.3 pmol/L; -32.2, -8.4; n = 11), and homeostasis model asse

144 ical scores; levels <133.3 pmol/l and >211.3 pmol/l detected low-risk and high-risk patients, respect

145 ble groups was determined to be 30.0 +/- 3.3 pmol.cm(-2), and copper-mediated azide-alkyne cycloaddit

146 ol/l (interquartile range [IQR]: 7.1 to 31.3 pmol/l), and the NT-proBNP level was >14 pmol/l in 53% o

147 kers, NT-proBNP in the upper quartile (>33.3 pmol/L) was most strongly associated with cardiovascular

148 PENK levels <48.3 pmol/l and >91 pmol/l detected low- and high-risk patien

149 992 +/- 1340, 14.1 +/- 4.9, and 66.1 +/- 7.3 pmol min(-1) mg protein(-1) in beta-TBECH.

150 een in patients with aortic coarctation (7.3 pmol/l [IQR: 2.8 to 19.5 pmol/l]).

151 (-6)) and fasting serum insulin (beta = -8.3 pmol l(-1), P = 0.0014), and their T2D risk is markedly

152 avenous infusions of arginine vasopressin (3 pmol.kg(-1).min(-1)), the selective vasopressin type 1a

153 odestly increased GLP-1 ( approximately 5-30 pmol/L).

154 that no loss of antisense activity above 30 pmol ASO was evident.

155 Vasopressin (3, 10, and 30 pmol/kg, IV) produced increased reduction in renal blood

156 , GLP-1-(9,36)amide, or exendin-(9,39) at 30 pmol/kg/min (Ex 30) or 300 pmol/kg/min (Ex 300) were inf

157 oaspartyl residues in yeast proteins (50-300 pmol of isoaspartyl residues/mg of protein extract) is c

158 d rat liver nuclei contain approximately 300 pmol of FAD.mg(-1) protein, which was mainly protein-bou

159 ce or absence of exendin-9,39 infused at 300 pmol/kg/min.

160 ndin-(9,39) at 30 pmol/kg/min (Ex 30) or 300 pmol/kg/min (Ex 300) were infused in random order on sep

161 kidney 293 (HEK) (Km 3.8 microM and Vmax 307 pmol/mg per minute) and HeLa (Km 0.32 microM and Vmax 42

162 00 pmol/L .min compared with 18,700 +/- 3100 pmol/L .min, P = 0.018).

163 es for 2-deoxy-d-glucose (Vmax of 224 and 32 pmol/min/oocyte for GLUT2 and GLUT8, respectively) and f

164 or iron deficiency (ferritin <15 ng/mL or 32 pmol/L), vitamin A deficiency (retinol-binding protein <

165 * min(-1) * m(-2) * mM(-1) vs. 44 [IQR, 32] pmol * min(-1) * m(-2) * mM(-1), P < 0.0001), and insuli

166 limit of detection from 10 nmol L(-1) to 320 pmol L(-1) streptavidin concentration with a much higher

167 /- 135 pmol/L for vitamin B-12 and 26 +/- 34 pmol/L for holotranscobalamin) than in the placebo group

168 sensitivity increased (median, 55 [IQR, 35] pmol * min(-1) * m(-2) * mM(-1) and 55 [IQR, 39] pmol *

169 hosphorylation rates ranging from 0.34 to 36 pmol min(-1) mg(-1) (n = 6).

170 ations increased from 222 pmol/L (62) to 364 pmol/L (222).

171 hormone levels (from 51 +/- 67 to 24 +/- 37 pmol/L, P<0.05) and phosphate.

172 (>1000 m) Pb concentrations were lower (6-37 pmol kg(-1)), and constituted a mix of background (natur

173 mg/dL, and fasting insulin concentration 37 pmol/L) were used.

174 ting plasma insulin concentrations (MD: 3.38 pmol/L; 95% CI: 0.03, 6.73 pmol/L; P < 0.05) and induced

175 and saturable binding capacity (Bmax), 6.38 pmol/mg protein.

176 * min(-1) * m(-2) * mM(-1) and 55 [IQR, 39] pmol * min(-1) * m(-2) * mM(-1) vs. 44 [IQR, 32] pmol *

177 ts, Bavail, appKD, and ED50 were 3.9 +/- 0.4 pmol/mL, 2.2 +/- 0.4 nM, and 12.0 +/- 2.6 nmol/kg, respe

178 ere higher in women (median of 21.7 vs. 10.4 pmol/l; p < 0.001).

179 echanical allodynia with an EC(5)(0) of 14.4 pmol.

180 D132 over a wide range of Hg/DOM ratios (9.4 pmol/mg DOM to 9.4 nmol/mg DOM), including environmental

181 nd 100 nmol/L with a limit of detection of 4 pmol/L.

182 r c-di-GMP levels of biofilm cells to </= 40 pmol mg(-1) correlated with increased susceptibility and

183 pmol/L .min compared with 68,100 +/- 11,400 pmol/L .min, P = 0.003) and 41% lower in subjects with T

184 ented concentrations ( approximately 300-400 pmol/L), drastically reducing glucose in Gipr null and L

185 characterized by 3DCC was approximately 400 pmol (836 ng).

186 SEM; incremental AUCinsulin 31,900 +/- 4100 pmol/L .min compared with 68,100 +/- 11,400 pmol/L .min,

187 minute) and HeLa (Km 0.32 microM and Vmax 42 pmol/mg per minute) cells.

188 the injection sites ranged from 371 to 1,441 pmol, which represented 16.5%-64.1% of the injected dose

189 creased to 43.7 +/- 8.02% on injection of 45 pmol/fly of BruIB.

190 The injection of 45 pmol/fly of each toxin dramatically decreases the respon

191 from approximately 35 to approximately 1,450 pmol/L).

192 bose and arabinose produced more PhIP (44-46 pmol of PhIP/mumol of creatinine).

193 alytes were 1.8, 1.0, 0.8, 2.2, 0.6, and 0.5 pmol, respectively, which correspond to LLOQs of 6, 3, 3

194 ly improved insulin secretion capacity (+0.5 pmol/L/min; 0.2, 0.8) whether replacing carbohydrate, SF

195 usion of either glucagon-like peptide-1 (1.5 pmol/kg/min) or normal saline plus intensive insulin the

196 3 to 160.5); transient ischemic attack 114.5 pmol/l (85.3 to 138.8); and nonischemic event 102.8 pmol

197 ic coarctation (7.3 pmol/l [IQR: 2.8 to 19.5 pmol/l]).

198 Radish microgreens in bags of 29.5 pmol s(-1) m(-2) Pa(-1) oxygen transmission rate (OTR) m

199 l and an upper limit of dynamic range of 3.5 pmol.

200 was also higher in patients at baseline (8.5 pmol/L [6.5-12.9] vs 4.6 pmol/L [3.5-5.5]), but the area

201 2 pmol of S(14)NO groups and approximately 5 pmol of S(15)NO groups for S-nitroso compounds in aqueou

202 At concentrations starting at 5 pmol per leaf, ZmPep3 stimulates production of jasmonic

203 th the upper limit of the dynamic range at 5 pmol.

204 ow the detection limit of <1 pmol L(-1) to 5 pmol L(-1), with average concentrations of between 0.5 a

205 either two 2-h hyperinsulinemic (812 +/- 50 pmol/L)-euglycemic (5 +/- 0.1 mmol/L) or hyperinsulinemi

206 0.1 mmol/L) or hyperinsulinemic (812 +/- 50 pmol/L)-hypoglycemic (2.9 +/- 0.1 mmol/L) clamps.

207 ns of "GLP-1 equivalents" ( approximately 50 pmol/L).

208 e adsorbed protein at the interface, from 50 pmol cm(-2), in the absence of surfactant, to 850 pmol c

209 sensitive assay is less than 15 pg/mL (< 50 pmol/L).

210 y of spin-labeled biomolecules (typically 50 pmol to 100 pmol) is quite challenging and often limits

211 Each 50-pmol/L increment in fasting insulin was associated with

212 limits of detection in the region of 100-500 pmol.

213 for non-species-specific ID LC-ICPMS and 500 pmol for species-specific ID GC/MS.

214 ithmic unit of the concentration between 500 pmol L(-1) and 10 nmol L(-1).

215 eased in the liver (from 100 pmol/g to 500 pmol/g) independent of adrenals.

216 oxide (iNOS) activity (LPS: 90.18 +/- 36.51 pmol/minute/mg protein versus LPS+HU: 16.37 +/- 4.73 pmo

217 feeding (392 +/- 53 compared with 326 +/- 54 pmol/L, respectively; P < 0.05).

218 nktonic cells to biofilm-like levels (>/= 55 pmol mg(-1) ) resulted in planktonic cells being signifi

219 s, a HEWL multilayer surface coverage of 550 pmol cm(-2) was formed, on the basis of the assumption t

220 rum holotranscobalamin (240 compared with 56 pmol/L), and 17% lower serum homocysteine (14.2 compared

221 risk of adverse clinical outcomes (MBG>/=574 pmol/L: hazard ratio 1.58 [1.10-2.31], P=0.014) even aft

222 ly after PPCI (2878+/-1461 versus 2213+/-579 pmol/L, P=0.04).

223 oth pathways were inhibited (from 3.1 to 1.6 pmol/100 blastocysts).

224 11%; -0.17, -0.05) and fasting insulin (-1.6 pmol/L; -2.8, -0.4).

225 pro-B-type natriuretic peptide (median: 11.6 pmol/l [interquartile range: 7.0 to 19.8 pmol/l]) was el

226 Binding was saturable (Bmax = 12.6 pmol/mg of protein) and reversible.

227 ts at baseline (8.5 pmol/L [6.5-12.9] vs 4.6 pmol/L [3.5-5.5]), but the area under the curve above ba

228 kers (DeltaTnI >121.8 mug/l; DeltaMPO >422.6 pmol/l).

229 .3 +/- 0.1 mmol/L) and insulinemia (46 +/- 6 pmol/L) during day 2 exercise studies, GABA A activation

230 Despite equivalent day 2 insulin (93 +/- 6 pmol/L) and glucose levels (5.3 +/- 0.1 mmol/L), plasma

231 neuronal discharges in response to 30 and 60 pmol cholecystokinin octapeptide were significantly lowe

232 ive, causing DTT to decay at a rate of 23-61 pmol min(-1) mug(-1) of particle used in the assay, whic

233 iol was checked and returned at 16 pg/mL (61 pmol/L); postmenopausal range for sensitive assay is les

234 ne group compared with the placebo group (64 pmol/L difference at 6- to 12-hour time point; 95% CI, -

235 he human lens at levels ranging from 0 to 64 pmol/mg lens.

236 ethod was validated (n = 18) at 5 mug/L (640 pmol/L) according to the Association of Official Racing

237 he response was linear from about 100 to 650 pmol.

238 ian 154 pmol/g) and food samples (median 0.7 pmol/g lw) but was below detection in serum samples, sug

239 uced in the NKB antagonist group (mean 112.7 pmol/L [SD 56.0] vs 240.1 [73.6], p=0.005): in keeping w

240 GLP-1 response [583 +/- 101 and 538 +/- 71 (pmol/L) x 120 min; P = 0.733], whereas the GIP response

241 ute/mg protein versus LPS+HU: 16.37 +/- 4.73 pmol/minute/mg protein; P <0.05); 2) tumor necrosis fact

242 rations (MD: 3.38 pmol/L; 95% CI: 0.03, 6.73 pmol/L; P < 0.05) and induced hepatic insulin resistance

243 ing plasma insulin concentrations (MD: -0.79 pmol/L; 95% CI: -6.41, 4.84 pmol/L; P = 0.78), the homeo

244 m) insulin concentration (254 pmol/L [88-797 pmol/L]), and median C-peptide concentration (2.4 nmol/L

245 re 11.8 +/- 4, 0.6 +/- 0.1, and 10.1 +/- 0.8 pmol min(-1) mg protein(-1) in TBECH mixture and 4992 +/

246 d intravenous saline (placebo) or GLP-1 (0.8 pmol/kg min), as a continuous 24-h infusion ("prolonged"

247 reased and urinary PGD-M levels (2.2 +/- 0.8 pmol/mg Cr, P < .001) decreased on 2 months of high-dose

248 tabolite (PGD-M; 13.6 +/- 2.7 vs 7.0 +/- 0.8 pmol/mg creatinine [Cr], P < .05) and thromboxane metabo

249 ion, insulin was infused portally (PoHI; 1.8 pmol/kg/min; n = 7) or peripherally (PeHI; 1.8 pmol/kg/m

250 ol/kg/min; n = 7) or peripherally (PeHI; 1.8 pmol/kg/min; n = 8) and insulin-327 (Pe327; 7.2 pmol/kg/

251 (85.3 to 138.8); and nonischemic event 102.8 pmol/l (76.4 to 137.6; both groups vs. stroke p < 0.05).

252 circulation (36.1 pmol/l [IQR: 14.4 to 103.8 pmol/l]) and a systemic right ventricle (RV) (31.1 pmol/

253 gnificantly higher compared to 13.8 +/- 11.8 pmol/L for postmenopausal women.

254 ailing controls (59.5+/-14.4 and 35.5+/-12.8 pmol/mg per minute, respectively).

255 : median (interquartile range), stroke 123.8 pmol/l (93 to 160.5); transient ischemic attack 114.5 pm

256 rated higher total PDE-specific (74.6+/-13.8 pmol/mg per minute) and PDE3-specific (48.2+/-15.9 pmol/

257 1.6 pmol/l [interquartile range: 7.0 to 19.8 pmol/l]) was elevated (>14 pmol/l) in 38% of patients.

258 evels of RCC patients and controls were 45.8 pmol/l and 45.1 pmol/l, respectively (p = 0.86).

259 an reductase (cortisone release 38.7 +/- 5.8 pmol/100 g/min).

260 The detection limit was 7.8 pmol.

261 (2 hr 3.5 [1.5-5.7] vs. 18 hr 1.2 [0.3-2.8] pmol/mL; P=0.010).

262 <80 pmol/L: beta=-0.013, p=1.6x10(-7); >/=80 pmol/L: beta=-0.008, p=1.8x10(-2), p for interaction 0.0

263 those with lower fasting insulin levels (<80 pmol/L: beta=-0.013, p=1.6x10(-7); >/=80 pmol/L: beta=-0

264 carbonate ions with a detection limit of 80 pmol L(-1) (5 ppt) and was utilized for direct determina

265 ol/L (n = 9); locally isolated 407 (126-830) pmol/L (n = 11); p = 0.32].

266 tions (MD: -0.79 pmol/L; 95% CI: -6.41, 4.84 pmol/L; P = 0.78), the homeostasis model assessment of i

267 ane F2alpha-III concentration was 176 +/- 85 pmol/L, and mean percentage of changes (95% CIs) were 1

268 cm(-2), in the absence of surfactant, to 850 pmol cm(-2), in the presence of 10 mM surfactant.

269 patients, with a starting median ARR of 8583 pmol/L per microg/(L . h) that normalized to 97 pmol/L p

270 of dye within the SLNs ranged from 8.5 to 88 pmol, which was equivalent to 0.38%-3.91% of the adminis

271 imately 50 muM and Vmax of approximately 0.9 pmol/min per ng of protein, and Rv1700 converts 8-oxo-dG

272 ncreased aldosterone secretion from mean 0.9 pmol/mug protein (SE 0.2) to 1.1 (0.1), whereas CYP11B2

273 g per minute) and PDE3-specific (48.2+/-15.9 pmol/mg per minute) activities in comparison with those

274 ased dramatically in group II (61.3 +/- 19.9 pmol/mg Cr, P < .05), whereas TX-M levels did not change

275 verage concentrations of between 0.5 and 2.9 pmol L(-1).

276 PENK levels <48.3 pmol/l and >91 pmol/l detected low- and high-risk patients, respectivel

277 et Icmt, with K(m) (6.6 muM) and V(max) (947 pmol min(-1) mg(-1)) values comparable or better than a-

278 31.1 pmol/l at baseline to 215.02 +/- 27.96 pmol/l at 6 h, p < 0.05).

279 l/L per microg/(L . h) that normalized to 97 pmol/L per microg/(L . h) (P < .01).

280 mol with the RSD lower than 5.70 % (n = 5 at pmol level).

281 cules within the concentration range between pmol and amol.

282 or potential confounders, cord blood log(FT3)pmol/L concentration was 0.11 lower in newborns of mothe

283 ) -0.08, -0.02] lower maternal serum log(FT4)pmol/L, whereas the medium TCS concentration was associa

284 mbinant cytoplasmic domain of BRI1 generates pmol amounts of cGMP per mug protein with a preference f

285 0.01) lower log-transformed fasting insulin (pmol/L) and 21% lower odds (95% confidence interval, 3-3

286 y weight, corresponding to an SA of 0.57 kBq/pmol.

287 dy weight, corresponding to an SA of 5.7 kBq/pmol for the given radioactivity dose, and 10% occupancy

288 Monthly erythrocyte TGN levels (pmol/8 x 108 erythrocytes) were measured over 6 consecut

289 al: -0.005, -0.003) and FI (beta = -0.008 ln-pmol/L, 95% confidence interval: -0.009, -0.007) levels

290 fasting glucose concentration and a 0.049-ln-pmol/L (95% CI: 0.035, 0.063-ln-pmol/L) higher fasting i

291 d a 0.049-ln-pmol/L (95% CI: 0.035, 0.063-ln-pmol/L) higher fasting insulin concentration.

292 atmospheric mole fractions ranging from low pmol/mol (parts-per-trillion; ppt) to nmol/mol (parts-pe

293 (APLI) with limits of detection in the lower pmol range.

294 23 +/- 25 [GLP-1] vs. 17 +/- 46 [saline] min pmol/L, P < 0.03) and endogenous glucose production was

295 adrenocorticotropic hormone ratio <3.0 (nmol/pmol).

296 127 vs. 955 +/- 166 10(-14) dL/kg/min(2) per pmol/L; P = 0.003).

297 nM and intrinsic clearance = 90 mul/min per pmol).

298 State III mitochondrial respiration rates (pmol O2/s/mg wet weight) were 15.05 +/- 3.92 and 11.42 +

299 Ten pmol/L GLP-1 increased both the spontaneous inhibitory p

300 droxy-2'-deoxyguanosine (8-OHdG) down to the pmol/L level.

301 /L), cytotoxicity-weighted sum of total THM (pmol/L), 4 THM in separate models, 4 THM in 1 model, chl

302 d as E2 greater than 10 pg/mL (to convert to pmol/L, multiply by 3.671) and at least 10 pg/mL above b